Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02759952Completed

Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial

Role: lead

NCT02610582Phase 1Active Not Recruiting

Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia

Role: lead

NCT04611503Phase 1Active Not Recruiting

PDE6A Gene Therapy for Retinitis Pigmentosa

Role: lead

NCT02671539Phase 2Completed

THOR - Tübingen Choroideremia Gene Therapy Trial

Role: lead

NCT01092533Phase 3Completed

Myfortic for the Treatment of Non-infectious Intermediate Uveitis

Role: lead

All 5 trials loaded